SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
SeaStar Medical (NASDAQ: ICU) announced a two-part video series featuring their QUELIMMUNE therapy at Cincinnati Children's Hospital Medical Center. The first video, available June 24, 2025, features Dr. Stuart Goldstein and CMO Dr. Kevin Chung discussing QUELIMMUNE's potential to reduce destructive hyperinflammation in organ failure cases.
The second video, releasing June 26, 2025, showcases a patient testimonial from Kurt and his father, describing Kurt's rapid recovery from post-heart surgery complications using QUELIMMUNE therapy. Both videos will be accessible through SeaStar Medical's investor relations website.
SeaStar Medical (NASDAQ: ICU) ha annunciato una serie video in due parti dedicata alla loro terapia QUELIMMUNE presso il Cincinnati Children's Hospital Medical Center. Il primo video, disponibile dal 24 giugno 2025, presenta il Dr. Stuart Goldstein e il CMO Dr. Kevin Chung che discutono del potenziale di QUELIMMUNE nel ridurre l'iperinfiammazione distruttiva nei casi di insufficienza d'organo.
Il secondo video, in uscita il 26 giugno 2025, mostra una testimonianza del paziente Kurt e di suo padre, che raccontano la rapida guarigione di Kurt dalle complicazioni post-intervento cardiaco grazie alla terapia QUELIMMUNE. Entrambi i video saranno disponibili sul sito web delle relazioni con gli investitori di SeaStar Medical.
SeaStar Medical (NASDAQ: ICU) anunció una serie de videos en dos partes que presenta su terapia QUELIMMUNE en el Cincinnati Children's Hospital Medical Center. El primer video, disponible el 24 de junio de 2025, cuenta con el Dr. Stuart Goldstein y el CMO Dr. Kevin Chung discutiendo el potencial de QUELIMMUNE para reducir la hiper inflamación destructiva en casos de fallo orgánico.
El segundo video, que se lanzará el 26 de junio de 2025, muestra el testimonio de un paciente, Kurt, y su padre, describiendo la rápida recuperación de Kurt de complicaciones post-cirugía cardíaca usando la terapia QUELIMMUNE. Ambos videos estarán accesibles a través del sitio web de relaciones con inversores de SeaStar Medical.
SeaStar Medical (NASDAQ: ICU)는 Cincinnati Children's Hospital Medical Center에서 QUELIMMUNE 치료법을 소개하는 2부작 영상 시리즈를 발표했습니다. 첫 번째 영상은 2025년 6월 24일에 공개되며, Dr. Stuart Goldstein와 최고 의료 책임자(Chief Medical Officer) Dr. Kevin Chung이 QUELIMMUNE이 장기 부전 사례에서 파괴적인 과염증을 줄일 수 있는 잠재력에 대해 논의합니다.
두 번째 영상은 2025년 6월 26일에 공개되며, 환자 Kurt와 그의 아버지가 출연하여 QUELIMMUNE 치료를 통해 심장 수술 후 합병증에서 빠르게 회복한 경험을 공유합니다. 두 영상 모두 SeaStar Medical의 투자자 관계 웹사이트에서 시청할 수 있습니다.
SeaStar Medical (NASDAQ : ICU) a annoncé une série vidéo en deux parties présentant leur thérapie QUELIMMUNE au Cincinnati Children's Hospital Medical Center. La première vidéo, disponible à partir du 24 juin 2025, met en scène le Dr Stuart Goldstein et le directeur médical Dr Kevin Chung discutant du potentiel de QUELIMMUNE à réduire l'hyperinflammation destructrice dans les cas d'insuffisance organique.
La deuxième vidéo, diffusée le 26 juin 2025, présente un témoignage du patient Kurt et de son père, décrivant la récupération rapide de Kurt des complications post-opératoires cardiaques grâce à la thérapie QUELIMMUNE. Les deux vidéos seront accessibles via le site web des relations investisseurs de SeaStar Medical.
SeaStar Medical (NASDAQ: ICU) hat eine zweiteilige Videoserie angekündigt, die ihre QUELIMMUNE-Therapie am Cincinnati Children's Hospital Medical Center vorstellt. Das erste Video, verfügbar ab dem 24. Juni 2025, zeigt Dr. Stuart Goldstein und den CMO Dr. Kevin Chung, die über das Potenzial von QUELIMMUNE sprechen, zerstörerische Hyperinflammation bei Organversagen zu reduzieren.
Das zweite Video, das am 26. Juni 2025 veröffentlicht wird, zeigt ein Patientenzeugnis von Kurt und seinem Vater, die Kurts schnelle Genesung von Komplikationen nach einer Herzoperation mit der QUELIMMUNE-Therapie beschreiben. Beide Videos sind über die Investor-Relations-Website von SeaStar Medical zugänglich.
- None.
- None.
Insights
SeaStar Medical's QUELIMMUNE adoption at Cincinnati Children's Hospital demonstrates clinical validation and market penetration for their hyperinflammation therapy.
SeaStar Medical's announcement about their QUELIMMUNE therapy features at Cincinnati Children's Hospital represents significant clinical validation for this commercial-stage product. Cincinnati Children's is a nationally recognized institution, and their adoption signals credibility within the pediatric critical care community.
The company is strategically showcasing both the institutional adoption angle and the patient success story, creating a dual narrative that addresses both the clinical and human aspects of their technology. This approach typically helps medical device companies build both clinical credibility and emotional resonance around their products.
QUELIMMUNE's mechanism of action - reducing destructive hyperinflammation that causes organ failure - targets a critical unmet need in critical care medicine. Hyperinflammatory responses leading to multi-organ failure have historically had limited treatment options with high mortality rates. The patient testimonial describing a "rapid recovery" following heart surgery complications suggests meaningful clinical outcomes.
For a commercial-stage healthcare company, these types of institutional adoptions at premier centers are crucial milestones that typically precede broader market penetration. Cincinnati Children's adoption may influence other pediatric centers to consider implementing QUELIMMUNE, potentially accelerating the commercial ramp. Patient testimonials featuring successful outcomes, especially in life-threatening scenarios, are powerful tools for driving clinical adoption of novel therapies.
While financial details aren't provided, this news indicates growing clinical implementation of SeaStar's flagship product, which is a fundamental value driver for medical device companies in the commercialization phase.
Cincinnati Children’s Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption
A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy
DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that the QUELIMMUNE therapy will be featured in a two-part video series that will be available on the SeaStar Medical website. The videos describe the adoption and the use of the QUELIMMUNE therapy for pediatric patients at the nationally recognized Cincinnati Children’s Hospital Medical Center and an interview with a father and his son, a pediatric patient in the ICU at Cincinnati Children’s who experienced a rapid recovery to good health following the use of the QUELIMMUNE therapy.
The events will be broadcast and can be viewed as followed:
- QUELIMMUNE Adoption: Stuart Goldstein, MD, FAAP, FNKF, at Cincinnati Children’s and Kevin Chung, MD, MACP, FCCM, Chief Medical Officer of SeaStar Medical, discuss QUELIMMUNE and its potential to reduce the destructive hyperinflammation that shuts down organs and takes lives.
- Available today, June 24, 2025, at 11:00 am Eastern Time on the Investor Relations section of Sea Star Medical’s website on the Events and Presentations page.
- A QUELIMMUNE Patient Journey: Following heart surgery for a congenital condition, Kurt’s recovery was impacted by a hyperinflammatory response by his immune system. Organ failure and respiratory distress set in. QUELIMMUNE therapy was administered, and Kurt and his father tell their story of Kurt’s rapid progress and recovery.
- Available June 26, 2025, at 11:00 am Eastern Time on the Investor Relations section of Sea Star Medical’s website on the Events and Presentations page.
About QUELIMMUNE
The QUELIMMUNE™ therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are being treated in the ICU with Renal Replacement Therapy (RRT). The QUELIMMUNE therapy was approved in February 2024 under a Humanitarian Device Exemption application, having met the applicable criteria with clinical results showing safety and probable clinical benefit in a limited population of critically ill children with AKI who have few treatment options. SeaStar Medical commenced its commercial launch of the QUELIMMUNE therapy in July 2025. In January 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of the QUELIMMUNE therapy.
About Acute Kidney Injury (AKI) and Hyperinflammation
AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as sepsis, severe trauma, surgery and COVID-19. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
IR@SEASTARMED.COM
FAQ
When will SeaStar Medical (ICU) release its QUELIMMUNE therapy video series?
What is the focus of SeaStar Medical's QUELIMMUNE therapy videos?
Who are the featured speakers in SeaStar Medical's QUELIMMUNE adoption video?
Where can investors watch SeaStar Medical's QUELIMMUNE video series?
